<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151407</url>
  </required_header>
  <id_info>
    <org_study_id>SSGJ-601-DME-I-01</org_study_id>
    <nct_id>NCT04151407</nct_id>
  </id_info>
  <brief_title>The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)</brief_title>
  <official_title>A Phase I , Multicenter, Open-Label, Single/Multiple Dose- Escalation Study of Recombinant Humanized Anti-VEGF Monoclonal Antibody Injection in Patients With Diabetic Macular Edema(DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observe the safety and tolerability of the single and multiple doses of 601 in DME patients;
      study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the
      Preliminary efficacy of 601 multiple injections with different doses in the treatment of
      patients with DME.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the results of preclinical pharmacological research and clinical application of
      bevacizumab in ophthalmology Case, 601 will be developed as a drug candidate for the
      treatment of ocular diseases such as DME .Observe the safety and tolerability of the single
      and multiple doses of 601 in DME patients; study the pharmacokinetic characteristics of
      single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple injections
      with different doses in the treatment of patients with DME.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>From Day 0 up to Day 28</time_frame>
    <description>Incidence of dose-limiting toxicities up to the Day 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>From Day 0 up to Day 56/112.</time_frame>
    <description>Maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>The maximum blood concentration after 601 drug enters the bloodstream</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>The half-life of drug 601, the time required for the terminal phase 601 drug concentration to drop by half</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>Area under the concentration-time curve, reflect the characteristics of the exposure of 601 drug in the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>The proportional constant between the amount of 601 drug in the body and the blood concentration when the 601 drug achieves the dynamic balance in the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>Clearance rate of drug 601 from the central ventricle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>The average length of time that the 601 drug stays in the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>the ratio of the amount of elimination of 601 drug from the body per unit time to the total amount in the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>Detection of VEGF concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From Day 0 up to 56/112 days</time_frame>
    <description>Development of Anti-drug antibodies (ADA) after IVT injection of 601</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>601 dose level 1 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>601 dose level 2 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>601 dose level 3 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>601 dose level 4 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>601 dose level 5 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>601 dose level 6 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>601 dose level 7 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug 601</intervention_name>
    <description>Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.</description>
    <arm_group_label>601 dose level 1 treatment</arm_group_label>
    <arm_group_label>601 dose level 2 treatment</arm_group_label>
    <arm_group_label>601 dose level 3 treatment</arm_group_label>
    <arm_group_label>601 dose level 4 treatment</arm_group_label>
    <arm_group_label>601 dose level 5 treatment</arm_group_label>
    <arm_group_label>601 dose level 6 treatment</arm_group_label>
    <arm_group_label>601 dose level 7 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign informed consent form and willing to be visited at the time specified in the
             trial

          -  Age &gt;= 18 years and age =&lt; 75 years

          -  Diagnosis of type 1 or type 2 diabetes

          -  Hemoglobin (HbA1c) value =&lt; 11%

          -  The study eye must meet the following criteria

               -  Diabetic macular edema with central fovea involvement and visual impairment in
                  subjects;

               -  Best corrected visual acuity letter score (ETDRS)&gt;= 19 (i.e., 20/400 or better)
                  and &lt;= 73 (i.e., 20/40 or worse)in the study eye;

               -  CRT ≥ 275 μm;

               -  No optometric media opacity and pupil shrinkage.

          -  Best corrected visual acuity letter score (ETDRS) &gt; =24 (i.e., 20/320 or better)in the
             fellow eyes

        Exclusion Criteria:

          -  Any eye has active ocular infections (e.g.,blepharitis, keratitis, scleritis,
             conjunctivitis);

          -  The study eye has proliferative diabetic retinopathy (PDR), except for the PDR with
             regression after panretinal photocoagulation, and Inactive, fibrotic PDR

          -  History of vitreous hemorrhage in the study eye within 2 months before screening

          -  Structural retinal damage with fovea in the study eye (e.g. retinal pigment
             epithelium(RPE) atrophy, retinal fibrosis, laser scarring, dense hard exudation), or
             researchers believe that the study eye has other retinal damage that may hinder visual
             improvement after macular edema subsides

          -  In addition to diabetic retinopathy, there are other causes of macular edema or visual
             changes in the study eye.

        Ophthalmic conditions (e.g.,retinal vein occlusion (RVO) Choroidal neovascularization,
        retinal detachment, macular hole, retinal traction in macular region, epiretinal membrane,
        etc.)

          -  Iris neovascularization in the study eye;

          -  Uncontrollable glaucoma in the study eye (defined as intraocular pressure after
             antiglaucoma medication&gt;= 25 mm Hg), or glaucoma filtering surgery history;

          -  Researchers believe that cataract in the study eye may affect the judgement of
             examination or test results, or surgical treatment is required in 6 months following
             screening

          -  The study eye has no lens( except intraocular lens)

          -  History of Intraocular injection for corticosteroids (e.g. triamcinolone) at any time
             in the past 3 months, or corticosteroids injection around the eyes within one month
             before screening

          -  History of vitrectomy in the studyeye

          -  History of panretinal photocoagulation in the study eye in the past 6 months before
             screening; or panretinal photocoagulation may be required following screening

          -  Study eye have received more than two local/grid retinal photocoagulation treatments,
             or history of local/grid retinal photocoagulation treatments in the study eye in the
             past 3 months before screening

          -  History of anti-VEGF drugs treatments(e.g. Abercept, Pigatani Sodium, Razumab,
             Bevacizumab, etc.) in any eye or system within 3 months before screening;

          -  History of any intraocular surgery (e.g. cataract surgery, YAG posterior capsulotomy,
             etc) in the study eye within 3 months before screening;

          -  History of ophthalmic surgery involving macular areas (e.g. PDT, macular
             transposition) in the study eye, except for local/grid retinal photocoagulation

        Any of the following general condition are present:

          -  Uncontrolled blood pressure control (defined as systolic blood pressure &gt; 150 mmHg or
             diastolic pressure &gt; 95 mmHg after antihypertensive medication

          -  The subjects is suffering from systemic infections and requiring oral, intramuscular
             or intravenous medication

          -  History of stroke, transient ischemic attack, myocardial infarction or acute
             congestive heart failure in the past 6 months before screening;

          -  Medicines with toxicity to the lens, retina or optic nerve (deferoxamine,
             chloroquine,hydroxychloroquine (chloroquine), tamoxifen and phenol etc.) is being used
             or may be used during the study period

          -  Diagnosed systemic immune diseases (e.g. ankylosing spondylitis and systemic lupus
             erythematosus etc.), or any uncontrolled clinical problem (e.g. AIDS, malignant
             tumors, active hepatitis, serious mental, neurological, cardiovascular, respiratory
             and other systemic diseases, etc.)

          -  History of allergy to fluorescein sodium and allergies to protein products for
             treatment or diagnosis, history of allergy to more than two drugs and/or non-drug
             factors, or suffering from allergic diseases now

        Any of the following laboratory tests abnormalities:

          -  Diabetic patients with uncontrolled blood glucose (fasting blood glucose &gt;= 8.8
             mmol/L);

          -  Renal function impairment (Cr is 1.5 times higher than the upper limit of normal
             values in the local laboratory) Liver dysfunction (ALT or AST is 2 times higher than
             the upper limit of normal value in the local laboratory).

          -  Abnormal coagulation function (prothrombin time &gt;= the upper limit of normal value for
             3 seconds) and activated partial thromboplastin time &gt;= the upper limit of normal
             value for 10 seconds)

        Patients with childbearing age with any of the following conditions:

        - Those who do not use effective contraceptive measures;

        The following are not excluded:

          1. Natural amenorrhea for more than 12 months, or natural amenorrhea for 6 months and the
             serum follicle-stimulating hormone level &gt; 40 mIU/mL;

          2. Bilateral ovariectomy with/without hysterectomy for more than 6 weeks;

          3. Use acceptable contraceptive methods(Sterilization, hormone contraception,Intrauterine
             device, double barrier method)

          4. Be able to use reliable contraceptives throughout the study period and stick to the
             end of the visit, (Unacceptable contraceptive methods include regular abstinence by
             calendar, ovulation, body temperature measurement, post-ovulation and fertilization in
             vitro);

               -  Pregnancy and lactation women (pregnancy is defined as urinary pregnancy test
                  positive in this study)

               -  Participation in any other drug clinical trials (except vitamins and minerals) in
                  the past 1 month before screening

               -  Researchers think it needs to be ruled out.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaodong Sun, PhD</last_name>
    <phone>+86-021-36216424</phone>
    <email>xdsun@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fenghua Wang, Doctor</last_name>
    <phone>+86-021-36216424</phone>
    <email>smilefh@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital of Central Theater.</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanPing Song, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ya Ye, Doctor</last_name>
      <phone>+86-027-50772574</phone>
      <email>470902810@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>YanPing Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huai Qing Liu, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>SongTao Yuan, Doctor</last_name>
      <phone>+86-025-83718836-3638</phone>
      <email>yuansongtao@vip.sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>QingHuai Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Sun, PHD</last_name>
    </contact>
    <contact_backup>
      <last_name>Fenghua Wang, Doctor</last_name>
      <phone>+86-021-36216424</phone>
      <email>smilefh@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaodong Sun, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>ChengDu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Zhang, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Fang Lu, Doctor</last_name>
      <phone>+86-028-85422452</phone>
      <email>lufang@medicail.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF; DME; bevacizumab; safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

